本文選題：結(jié)直腸癌　切入點(diǎn)：EGFR抑制劑　出處：《河北醫(yī)科大學(xué)》2017年碩士論文

【摘要】：結(jié)直腸癌是最常見(jiàn)的惡性腫瘤之一。隨著分子生物學(xué)技術(shù)飛速發(fā)展,以分子靶向治療為主的個(gè)體化治療在結(jié)直腸癌治療中占據(jù)了重要的地位。近年來(lái),作用于EGFR、VEGF和c-Met等位點(diǎn)的新型靶向藥物不斷進(jìn)入臨床試驗(yàn),層出不窮的研究在不停地探索靶向藥物聯(lián)合傳統(tǒng)化療、免疫治療以及不同靶向藥物聯(lián)合使用的療效,以期通過(guò)高效低毒的治療手段為患者帶來(lái)最大的生存獲益。本文總結(jié)了近年來(lái)結(jié)直腸癌分子靶向治療的臨床新進(jìn)展,并對(duì)靶向藥物的發(fā)展趨勢(shì)進(jìn)行了展望。
[Abstract]:Colorectal cancer is one of the most common malignant tumors.With the rapid development of molecular biology technology, individualized therapy with molecular targeted therapy plays an important role in the treatment of colorectal cancer.In recent years, new targeting drugs acting on the allelic sites of EGFR and c-Met have been continuously introduced into clinical trials, and numerous studies have been carried out to explore the efficacy of targeting drugs in combination with traditional chemotherapy, immunotherapy and combination of different targeted drugs.In order to achieve maximum survival benefits through effective and low-toxic treatment.In this review, the recent advances in molecular targeted therapy for colorectal cancer were reviewed, and the development trend of targeted drugs was prospected.
【學(xué)位授予單位】：河北醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R735.34

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 Yoshihito Ohhara;Naoki Fukuda;Satoshi Takeuchi;Rio Honma;Yasushi Shimizu;Ichiro Kinoshita;Hirotoshi Dosaka--Akita;;Role of targeted therapy in metastatic colorectal cancer[J];World Journal of Gastrointestinal Oncology;2016年09期

2 Yu-Wen Zhang;;Promise and challenges on the horizon of MET-targeted cancer therapeutics[J];World Journal of Biological Chemistry;2015年02期

，

本文編號(hào)：1709404